Ten‐year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience
Haemophilia · 2026-11 · 32 (6) · 1471-1480
DOI: 10.1111/hae.70344 ↗Abstract
ABSTRACT Background The Colombian Registry of Haemophilia and other Coagulopathies (CRHOC) was established in 2014 to centralize nationwide data on haemophilia patients through mandatory reporting by all treatment centres and healthcare payers. Objective To describe 10‐year trends in epidemiological patterns, treatment access, and health outcomes among individuals with haemophilia reported to the CRHOC. Methods This longitudinal analysis included all haemophilia patients reported to the CRHOC between February 2014 and January 2024. Sociodemographic and clinical characteristics, treatment patterns, and quality‐of‐care indicators were analysed. Data underwent standardized quality assurance procedures, including validation frameworks and medical record verification. Results From 2014 to 2024, 3699 people with haemophilia were reported (83.1% haemophilia A; 16.9% haemophilia B). Prevalence increased over time, while prevalence of high‐titre inhibitor declined for both types. Prophylaxis coverage exceeded 95% in children and 85% in adults with severe haemophilia. Treatment patterns shifted notably, with increased adoption of extended half‐life products and emicizumab for haemophilia A. The prevalence of chronic arthropathy remained stable in children but increased in adults, despite widespread use of prophylaxis. Access to multidisciplinary care improved significantly over the decade. Conclusion Over ten years, the CRHOC has documented substantial improvements in haemophilia care in Colombia, including near‐universal access to prophylaxis, reduced inhibitor prevalence, and increased use of innovative therapies. The consistent expansion of multidisciplinary care has enhanced patient management. As a comprehensive national registry, the CRHOC provides high‐quality data to inform evidence‐based health policy decisions and serves as a model for improving clinical outcomes in rare disease management.
EUVIMED